Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen

CAR-T Digest - August 2020

11 July 2024: Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen

Ipsen secured global rights from Foreseen Biotechnology in a $1 billion-plus deal to develop and commercialize FS001, an antibody-drug conjugate (ADC) targeting a novel antigen prevalent in solid tumors
FS001 has demonstrated efficacy in preclinical studies against multi-drug resistant cancer models, showing promise for treating various solid tumor types
Ipsen will now oversee Phase I clinical trial preparations, IND application submission, and subsequent clinical development, manufacturing, and commercialization efforts for FS001
This agreement marks Ipsen’s second significant move into the ADC space this year, following a similar deal with Sutro Biopharma for STRO-003, which targets the ROR1 tumor antigen
The global ADC market, which exceeded $10 billion in 2023, is projected to reach $30 billion by 2028, highlighting significant investment and growth potential in the sector